Login Register
icon_bulk_orderBulk order Acrobiosystems for English
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > -

-

Licensing

Project item Indications Research phase Cooperation demands
BHE202219 Idiopathic pulmonary fibrosis (IPF) and solid tumor, (FDA ODD) Phase 1 License-out or co-development
BNO202203 IBD, expanded indication COVID-19 IND ready License-out or co-development
BHE202203 Hyperuricemia (HUA) Phase 1 is ongoing in China License-out or co-development
BHE202214 Diabetic kidney disease Phase I is ongoing in China Out licensing global right
BHE202211 Hematologic malignancies Phase I, China; the patent has been granted in the US License-out and co-development
NSS21001 Cancer Cachexia Preclinical License-out or co-development the global right
BHE202206 Depression Phase II/ III License-out or co-development
BHE202217 Migraine Phase 1 License-out or co-development
BHE202205 NASH Phase I is finished in AU/Phase II is ongoing in CN License-out or co-development
BHE202220 NASH IND, IP has been granted in the US, CN, etc License-out or co-development the global right
BHE202216 HBV Phase 1 License-out or co-development
BHE202218 CKD and Renal anemia Phase 1 License-out or co-development of the global right (except for China)
BHE202213 Pulmonary arterial hypertension (PAH), Chronic thromboembolic pulmonary hypertension (CTEPH), Heart failure with reduced ejection fraction (HFrEF), Chronic kidney disease (CKD) Phase 1, IP has been granted in US, AU, CN License-out or co-development
BHE202208 Diabetes Phase III Out licensing global right
BHE202207 HBV Phase 3 China, Phase 2, US License-out or co-development
BDA202205 bacterial infections caused by specific microbial sensitive strains, such as complex or non-complex skin and skin soft tissue infections, community/hospital acquired pneumonia, vancomycin-resistant enterococcal infections, other bone and joint infections, IND License-out or co-development the global right
BHE202202 NSCLC, Medullary thyroid cancer, Thyroid cancer Phase 1 License-out or co-development

Product ListCompare or Buy

By Product Status:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
CHEK-SP01 0 HEK293F Cell Line
DB-02 - Dilution Buffer (Strengthen Blocking)
FCM-B01M - 96-Well Filter Plate
ACRO Quality

Part of Bioactivity data

DB-02-MALS-HPLC
 - ELISA

2% serum diluted by Dilution Buffer : Biotinylated SARS-CoV-2 S protein RBD was put into, the background value is 2.383 and 2.148; 2% serum diluted by DB-02 : Biotinylated SARS-CoV-2 S protein RBD was put into, the background value is 0.262 and 0.263. In the existence of DB-02, the serum background values significantly decreased. Note: Dilution Buffer is Wash Buffer with 0.5% (w/v) bovine serum albumin (BSA), 50 mL.

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message